Christian Hansen
Plus aucun poste en cours
Profil
Christian Hansen is co-founder and partner of Nordic Biotech.
Dr. Hansen has a background as a biotech entrepreneur, biotech intellectual property rights expert and business development executive, combined with a scientific career.
He has been actively involved in biotech investment since the late 1990’s.
From 2000 to 2001 Dr. Hansen was President of Maxygen's Protein Pharma Division, and Managing Director of its Danish subsidiary Maxygen ApS, employing about 75 people.
From 1999 to 2000, Dr. Hansen was CEO and founder of ProFound Pharma A/S, a Danish start-up company focused on developing 2nd generation protein pharmaceuticals.
From 1992 to 1999, Dr. Hansen held executive positions at Novo Nordisk A/S, including as Director of Intellectual Property Strategy, which is one of his core areas of expertise.
In this capacity, Dr. Hansen was responsible for numerous patent, license and collaborative agreement strategies and negotiations, and was a member of Research Management.
Dr. Hansen holds an MSc (1989) in chemical engineering, a PhD (1992) in molecular biology/biochemistry and an MBA.
Anciens postes connus de Christian Hansen
| Sociétés | Poste | Fin |
|---|---|---|
Blue Note Pharmaceuticals BV
 Blue Note Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Blue Note Pharmaceuticals is a privately held biopharmaceutical company with offices in Troy, New York and Amsterdam, The Netherlands. Blue Note's mission is to acquire, advance, develop, partner and commercialize carefully selected undervalued drug development candidates with the potential to more effectively treat or help prevent major medical conditions affecting society. The Company's lead development project is BNP 32,762, a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina. Blue Note is also evaluating various products that would combine BNP 32,762 with other commonly accepted antihypertensive drugs such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and diuretics. The Company's cardiovascular-oriented pipeline also includes an early-stage program for the prevention of Deep Vein Thrombosis (DVT) and for the treatment of a number of other important cardiovascular indications. | Directeur/Membre du Conseil | 04/02/2014 |
Nordic Biotech Advisors ApS
 Nordic Biotech Advisors ApS Investment ManagersFinance Nordic Biotech Advisors ApS (NB Capital) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2001 by Florian Schönharting and Dr. Christian Hansen, and is owned by a group of institutional investors. | Private Equity Investor | 31/12/2013 |
Rose Pharma A/S
 Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Rose Pharma A/S provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome. It develops treatments for irritable bowel syndrome (IBS) and functional dyspepsia, and disorders. The firm focuses on the medical applications of gastrointestinal hormones. The company was founded in 2003 and is headquartered in Roskilde, Denmark. | Directeur/Membre du Conseil | 27/06/2012 |
Aditech Pharma AB
 Aditech Pharma AB Pharmaceuticals: MajorHealth Technology Aditech Pharma AB develops and manufactures pharmaceutical products. It offers furmaric acid esters used for the treatment of psoriasis, inflammatory, and autoimmune disorders. The company is headquartered in Tygelsjo, Sweden | President | 13/04/2010 |
| OSTEOLOGIX HOLDINGS PLC | Directeur/Membre du Conseil | 29/12/2009 |
Formation de Christian Hansen
| The University of Edinburgh | Masters Business Admin |
| Technical University of Denmark | Graduate Degree |
| University of Strasbourg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| Entreprise privées | 9 |
|---|---|
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
| Osteologix, Inc. /Old/ | Health Technology |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Health Technology |
Nordic Biotech Advisors ApS
Nordic Biotech Advisors ApS Investment ManagersFinance Nordic Biotech Advisors ApS (NB Capital) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2001 by Florian Schönharting and Dr. Christian Hansen, and is owned by a group of institutional investors. | Finance |
Rose Pharma A/S
Rose Pharma A/S Pharmaceuticals: MajorHealth Technology Rose Pharma A/S provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome. It develops treatments for irritable bowel syndrome (IBS) and functional dyspepsia, and disorders. The firm focuses on the medical applications of gastrointestinal hormones. The company was founded in 2003 and is headquartered in Roskilde, Denmark. | Health Technology |
Osteologix Holdings Plc
 Osteologix Holdings Plc Pharmaceuticals: OtherHealth Technology Osteologix Holdings Plc engaged in the development of innovative pharmaceuticals for the treatment and prevention of bone and joint tissues diseases. The company was founded in October 2004 and was headquartered in Dublin, Ireland. | Health Technology |
Forward Pharma A/S
 Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark. | Health Technology |
Blue Note Pharmaceuticals BV
Blue Note Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Blue Note Pharmaceuticals is a privately held biopharmaceutical company with offices in Troy, New York and Amsterdam, The Netherlands. Blue Note's mission is to acquire, advance, develop, partner and commercialize carefully selected undervalued drug development candidates with the potential to more effectively treat or help prevent major medical conditions affecting society. The Company's lead development project is BNP 32,762, a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina. Blue Note is also evaluating various products that would combine BNP 32,762 with other commonly accepted antihypertensive drugs such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and diuretics. The Company's cardiovascular-oriented pipeline also includes an early-stage program for the prevention of Deep Vein Thrombosis (DVT) and for the treatment of a number of other important cardiovascular indications. | Health Technology |
Aditech Pharma AB
Aditech Pharma AB Pharmaceuticals: MajorHealth Technology Aditech Pharma AB develops and manufactures pharmaceutical products. It offers furmaric acid esters used for the treatment of psoriasis, inflammatory, and autoimmune disorders. The company is headquartered in Tygelsjo, Sweden | Health Technology |
